Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Receivables - Net (2022 - 2025)

Historic Receivables - Net for Autolus Therapeutics (AUTL) over the last 4 years, with Q3 2025 value amounting to $32.6 million.

  • Autolus Therapeutics' Receivables - Net changed N/A to $32.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.6 million, marking a year-over-year change of. This contributed to the annual value of $15000.0 for FY2024, which is 8623.85% down from last year.
  • Autolus Therapeutics' Receivables - Net amounted to $32.6 million in Q3 2025.
  • In the past 5 years, Autolus Therapeutics' Receivables - Net registered a high of $32.6 million during Q3 2025, and its lowest value of $15000.0 during Q4 2024.
  • Over the past 4 years, Autolus Therapeutics' median Receivables - Net value was $165000.0 (recorded in 2023), while the average stood at $10.6 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first crashed by 991.74% in 2023, then crashed by 8623.85% in 2024.
  • Autolus Therapeutics' Receivables - Net (Quarter) stood at $121000.0 in 2022, then decreased by 9.92% to $109000.0 in 2023, then plummeted by 86.24% to $15000.0 in 2024, then soared by 217260.0% to $32.6 million in 2025.
  • Its last three reported values are $32.6 million in Q3 2025, $26.6 million for Q2 2025, and $14.3 million during Q1 2025.